A Study of Navenibart in Participants With Hereditary Angioedema
This research study, called a Phase 3 trial, is looking at a new medicine called navenibart for people who have Hereditary Angioedema (HAE). HAE is a rare condition that causes sudden swelling attacks. The main goal is to find out if navenibart can safely and effectively stop these swelling attacks from happening in both adults and teenagers. Some participants will receive navenibart, while others will receive a placebo (a dummy treatment with no active medicine). This helps researchers compare the effects fairly. It’s a ‘double-blind’ study, meaning neither the participants nor the doctors will know who is getting the actual medicine and who is getting the placebo.
במבט חטוף
על מה המחקר הזה?
This important study is testing a new treatment called navenibart for a condition known as Hereditary Angioedema, often shortened to HAE. HAE is a genetic condition that causes sudden, unpredictable swelling attacks in different parts of the body, such as the skin, stomach, or throat. These attacks can be painful, debilitating, and sometimes even life-threatening, especially if the swelling affects the airways.
The main aim of this study is to see if navenibart can help prevent these swelling attacks from happening. Researchers are also very keen to understand if the medicine is safe. They will compare navenibart with a 'placebo' – which looks just like the real medicine but contains no active ingredients. This is a standard way to find out if the new medicine really works better than no treatment.
This study is a 'Phase 3' trial, which means it's one of the final steps before a new medicine might be approved for wider use. It involves many medical centres and participants, carefully looking at how navenibart works in adults and teenagers who have HAE type 1 or type 2. If successful, navenibart could offer a new way to help manage HAE and improve the lives of those affected.
נקודות עיקריות
- This study is testing a new medicine, navenibart, for Hereditary Angioedema (HAE).
- Its main goal is to prevent HAE swelling attacks in adults and teenagers.
- Participants will receive either navenibart or a placebo (dummy treatment).
- It's a 'Phase 3' study, aiming to confirm safety and effectiveness.
- Regular clinic visits and self-monitoring of HAE attacks will be required.
מי עשוי להיות זכאי?
To join this study, you must have a confirmed diagnosis of Hereditary Angioedema (HAE), either type 1 or type 2. This means your doctor will have found evidence of HAE from your medical history and specific blood tests.
During a short period before the main study, called a 'run-in' period, you would have needed to experience at least two HAE swelling attacks. This helps the researchers understand your typical attack pattern before you start any new treatment.
There are also some reasons why you wouldn't be able to join. For example, if you have other types of swelling conditions that mimic HAE, or if you've recently used certain other medicines for preventing HAE attacks. You would need to stop these other preventative medicines for a set time before the study begins, under the guidance of the study doctors.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- Do you have a doctor-confirmed diagnosis of Hereditary Angioedema (HAE) Type 1 or Type 2?
- Have you had at least two HAE attacks recorded by a doctor very recently?
- האם אתה בן 12 שנים או יותר?
- Do you currently have any other swelling conditions like HAE type 3?
- Have you recently used certain other medicines to prevent HAE attacks (your doctor can advise on specific timeframes)?
מה כרוך בהשתתפות?
If you join the study, you will receive either the new medicine, navenibart, or a placebo, given as an injection under the skin. You won't know which one you're getting, and neither will your study doctor – this is to make sure the results are as fair and unbiased as possible. Over the course of the study, you'll have regular visits to the clinic so the medical team can monitor your health, check for any side effects, and see how many HAE attacks you experience. You will also need to keep a record of your HAE attacks at home. The total duration of your participation in this study will be explained in detail by the study team, including how often you'll need to attend appointments and how long the treatment period will last, along with any follow-up checks.
סיכונים ותועלות פוטנציאליים
Locations (86)
- Site 9מיקוד מאומתבירמינגהם, ארצות הברית
- Site 2מיקוד מאומתסקוטסדייל, ארצות הברית
- Site 3מיקוד מאומתליטל רוק, ארצות הברית
- Site 26מיקוד מאומתסן דייגו, ארצות הברית
- Site 14מיקוד מאומתסן דייגו, ארצות הברית
- Site 4מיקוד מאומתסנטה מוניקה, ארצות הברית
- Site 1מיקוד מאומתוולנאט קריק, ארצות הברית
- Site 8מיקוד מאומתCentennial, United States
- Site 11מיקוד מאומתקולורדו ספרינגס, ארצות הברית
- Site 25מיקוד מאומתטמפה, ארצות הברית
- Site 69מיקוד מאומתWeston, United States
- Site 6מיקוד מאומתWheaton, United States
שאלות נפוצות
What is Hereditary Angioedema (HAE)?
HAE is a rare genetic condition that causes sudden, unpredictable swelling in different parts of your body, like your skin, bowels, or throat.
What is a 'Phase 3' clinical trial?
It's one of the final stages of testing a new medicine, involving many people, to confirm its safety and effectiveness before it might be made available to everyone.
מהו 'פלצבו'?
A placebo looks exactly like the study medicine but contains no active ingredients. It helps researchers understand if the new medicine is truly effective.
האם אדע אם אני מקבל את התרופה האמיתית או את הפלצבו?
No, neither you nor your study doctor will know. This is called 'double-blind' and helps ensure the study results are accurate and fair.
What is 'navenibart'?
Navenibart is the name of the new investigational medicine being tested in this study to prevent HAE attacks.
כיצד לגלות עוד
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.